Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes, Gestational | 14 | 2026 | 330 | 4.670 |
Why?
|
| Pregnancy | 29 | 2026 | 1555 | 2.260 |
Why?
|
| Premature Birth | 3 | 2023 | 133 | 1.460 |
Why?
|
| Female | 39 | 2026 | 12193 | 1.410 |
Why?
|
| Adult | 27 | 2026 | 7255 | 1.380 |
Why?
|
| Humans | 44 | 2026 | 16832 | 1.370 |
Why?
|
| Biosensing Techniques | 2 | 2022 | 3 | 1.330 |
Why?
|
| MicroRNAs | 2 | 2022 | 17 | 1.320 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 45 | 1.190 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2019 | 18 | 1.170 |
Why?
|
| Life Style | 3 | 2021 | 305 | 1.170 |
Why?
|
| Eclampsia | 2 | 2026 | 13 | 1.160 |
Why?
|
| Pre-Eclampsia | 2 | 2026 | 41 | 1.110 |
Why?
|
| Blood Glucose | 5 | 2026 | 315 | 1.050 |
Why?
|
| Obesity | 4 | 2026 | 811 | 1.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 6 | 2026 | 206 | 0.960 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2021 | 677 | 0.960 |
Why?
|
| Obesity, Abdominal | 1 | 2026 | 14 | 0.950 |
Why?
|
| Pediatric Obesity | 3 | 2026 | 101 | 0.940 |
Why?
|
| Prospective Studies | 10 | 2026 | 1186 | 0.930 |
Why?
|
| Metabolome | 1 | 2025 | 3 | 0.920 |
Why?
|
| Environmental Pollutants | 5 | 2026 | 68 | 0.910 |
Why?
|
| Microbiota | 1 | 2025 | 10 | 0.910 |
Why?
|
| Fetal Development | 1 | 2025 | 15 | 0.910 |
Why?
|
| Cohort Studies | 11 | 2026 | 2396 | 0.900 |
Why?
|
| Ethnic Groups | 2 | 2019 | 418 | 0.900 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2025 | 40 | 0.880 |
Why?
|
| Food Assistance | 1 | 2025 | 10 | 0.860 |
Why?
|
| Maternal Exposure | 4 | 2026 | 84 | 0.840 |
Why?
|
| Vaginal Birth after Cesarean | 1 | 2024 | 3 | 0.840 |
Why?
|
| Risk Factors | 10 | 2026 | 3108 | 0.830 |
Why?
|
| Electronic Health Records | 3 | 2025 | 702 | 0.820 |
Why?
|
| Algorithms | 1 | 2025 | 210 | 0.810 |
Why?
|
| Signal Transduction | 2 | 2021 | 29 | 0.780 |
Why?
|
| Longitudinal Studies | 6 | 2025 | 653 | 0.760 |
Why?
|
| Triclosan | 1 | 2022 | 4 | 0.750 |
Why?
|
| Pregnancy Complications | 2 | 2025 | 202 | 0.750 |
Why?
|
| Prenatal Care | 2 | 2021 | 123 | 0.730 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 34 | 0.730 |
Why?
|
| Hypertension | 2 | 2026 | 475 | 0.730 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 445 | 0.720 |
Why?
|
| Young Adult | 9 | 2026 | 2456 | 0.710 |
Why?
|
| Body Mass Index | 7 | 2026 | 925 | 0.690 |
Why?
|
| Preconception Care | 1 | 2021 | 43 | 0.670 |
Why?
|
| Infant, Newborn | 6 | 2025 | 828 | 0.650 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 2 | 0.630 |
Why?
|
| NF-kappa B | 1 | 2020 | 9 | 0.620 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 5 | 0.620 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 6 | 0.620 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2020 | 1 | 0.620 |
Why?
|
| Eicosanoids | 1 | 2020 | 1 | 0.620 |
Why?
|
| Sirtuin 1 | 1 | 2020 | 1 | 0.620 |
Why?
|
| Reperfusion Injury | 1 | 2020 | 2 | 0.620 |
Why?
|
| Thinness | 1 | 2020 | 31 | 0.620 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2020 | 6 | 0.620 |
Why?
|
| Olmesartan Medoxomil | 1 | 2019 | 1 | 0.610 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 8 | 0.610 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2019 | 2 | 0.610 |
Why?
|
| Phospholipids | 1 | 2019 | 3 | 0.610 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2019 | 10 | 0.600 |
Why?
|
| Nutritional Status | 1 | 2019 | 32 | 0.600 |
Why?
|
| Diabetic Nephropathies | 1 | 2019 | 24 | 0.600 |
Why?
|
| Male | 19 | 2026 | 9556 | 0.600 |
Why?
|
| Platinum | 1 | 2019 | 1 | 0.590 |
Why?
|
| Metal Nanoparticles | 1 | 2019 | 1 | 0.590 |
Why?
|
| Immobilized Nucleic Acids | 1 | 2019 | 1 | 0.590 |
Why?
|
| DNA Probes | 1 | 2019 | 2 | 0.590 |
Why?
|
| Postpartum Period | 5 | 2026 | 89 | 0.570 |
Why?
|
| Cardiovascular System | 1 | 2018 | 3 | 0.570 |
Why?
|
| Healthy Aging | 1 | 2018 | 11 | 0.560 |
Why?
|
| California | 6 | 2026 | 2244 | 0.550 |
Why?
|
| Health Status Disparities | 1 | 2019 | 145 | 0.540 |
Why?
|
| Fetal Macrosomia | 1 | 2017 | 27 | 0.510 |
Why?
|
| Attitude to Health | 1 | 2017 | 142 | 0.470 |
Why?
|
| Animals | 4 | 2020 | 237 | 0.460 |
Why?
|
| Pregnancy Outcome | 4 | 2025 | 160 | 0.450 |
Why?
|
| Organophosphates | 2 | 2026 | 20 | 0.450 |
Why?
|
| Flame Retardants | 2 | 2026 | 20 | 0.450 |
Why?
|
| Prevalence | 4 | 2026 | 785 | 0.450 |
Why?
|
| Depression | 5 | 2026 | 479 | 0.440 |
Why?
|
| Glycated Hemoglobin A | 3 | 2020 | 176 | 0.430 |
Why?
|
| Gestational Age | 3 | 2025 | 118 | 0.420 |
Why?
|
| Fluorocarbons | 2 | 2025 | 20 | 0.420 |
Why?
|
| Phenols | 2 | 2026 | 42 | 0.420 |
Why?
|
| Case-Control Studies | 5 | 2025 | 995 | 0.420 |
Why?
|
| Child, Preschool | 8 | 2026 | 1430 | 0.390 |
Why?
|
| Child | 9 | 2026 | 2433 | 0.390 |
Why?
|
| Autistic Disorder | 2 | 2026 | 117 | 0.390 |
Why?
|
| Self Report | 2 | 2018 | 248 | 0.370 |
Why?
|
| Prediabetic State | 2 | 2026 | 63 | 0.360 |
Why?
|
| Autism Spectrum Disorder | 2 | 2025 | 165 | 0.350 |
Why?
|
| Electrochemical Techniques | 2 | 2022 | 2 | 0.330 |
Why?
|
| Limit of Detection | 2 | 2022 | 2 | 0.330 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2022 | 3 | 0.330 |
Why?
|
| Mice | 2 | 2020 | 59 | 0.310 |
Why?
|
| Creatinine | 2 | 2020 | 67 | 0.300 |
Why?
|
| Stress, Psychological | 3 | 2025 | 136 | 0.290 |
Why?
|
| Communication | 2 | 2020 | 183 | 0.290 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 186 | 0.280 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2025 | 55 | 0.280 |
Why?
|
| Middle Aged | 8 | 2025 | 7515 | 0.270 |
Why?
|
| Self Care | 1 | 2018 | 139 | 0.260 |
Why?
|
| Cesarean Section | 2 | 2025 | 34 | 0.260 |
Why?
|
| Aged | 6 | 2022 | 5901 | 0.260 |
Why?
|
| Patient Participation | 1 | 2018 | 120 | 0.260 |
Why?
|
| Plasticizers | 1 | 2026 | 5 | 0.240 |
Why?
|
| Phenotype | 1 | 2026 | 105 | 0.240 |
Why?
|
| Pregnancy Trimester, First | 1 | 2026 | 45 | 0.240 |
Why?
|
| Medical Informatics | 1 | 2016 | 34 | 0.240 |
Why?
|
| Mexican Americans | 1 | 2026 | 43 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 352 | 0.240 |
Why?
|
| Adolescent | 4 | 2025 | 3464 | 0.230 |
Why?
|
| Bayes Theorem | 2 | 2023 | 75 | 0.230 |
Why?
|
| Urban Population | 1 | 2016 | 105 | 0.230 |
Why?
|
| Prenatal Diagnosis | 1 | 2025 | 20 | 0.230 |
Why?
|
| Pregnancy in Diabetics | 1 | 2025 | 19 | 0.230 |
Why?
|
| Glucose Intolerance | 1 | 2025 | 45 | 0.230 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2025 | 13 | 0.230 |
Why?
|
| Parabens | 1 | 2025 | 5 | 0.220 |
Why?
|
| Poverty | 1 | 2016 | 167 | 0.220 |
Why?
|
| United States | 3 | 2024 | 3858 | 0.220 |
Why?
|
| Hispanic Americans | 1 | 2016 | 350 | 0.210 |
Why?
|
| Child Development | 1 | 2024 | 58 | 0.200 |
Why?
|
| African Americans | 1 | 2016 | 394 | 0.200 |
Why?
|
| Phenol | 1 | 2022 | 4 | 0.190 |
Why?
|
| Endonucleases | 1 | 2022 | 3 | 0.190 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 27 | 0.190 |
Why?
|
| DNA | 1 | 2022 | 25 | 0.180 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 8 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2020 | 9 | 0.180 |
Why?
|
| Rats | 2 | 2020 | 33 | 0.180 |
Why?
|
| Kidney | 2 | 2020 | 51 | 0.170 |
Why?
|
| Glycolysis | 1 | 2021 | 1 | 0.170 |
Why?
|
| Up-Regulation | 1 | 2021 | 5 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 4 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 14 | 0.170 |
Why?
|
| Hypoxia | 1 | 2021 | 7 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 346 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 40 | 0.160 |
Why?
|
| Pandemics | 4 | 2023 | 289 | 0.160 |
Why?
|
| Apoptosis | 1 | 2020 | 11 | 0.160 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 17 | 0.160 |
Why?
|
| Mass Screening | 1 | 2025 | 670 | 0.160 |
Why?
|
| Blood Urea Nitrogen | 1 | 2020 | 8 | 0.160 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 3 | 0.150 |
Why?
|
| Albuminuria | 1 | 2019 | 39 | 0.150 |
Why?
|
| Inverted Repeat Sequences | 1 | 2019 | 1 | 0.150 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2019 | 2 | 0.150 |
Why?
|
| Calibration | 1 | 2019 | 8 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 130 | 0.150 |
Why?
|
| Feedback | 1 | 2019 | 22 | 0.150 |
Why?
|
| Consumer Behavior | 1 | 2019 | 27 | 0.140 |
Why?
|
| Qualitative Research | 2 | 2021 | 288 | 0.140 |
Why?
|
| Minority Groups | 1 | 2019 | 99 | 0.140 |
Why?
|
| Insulin | 1 | 2019 | 181 | 0.140 |
Why?
|
| Insulin Resistance | 1 | 2019 | 127 | 0.140 |
Why?
|
| Text Messaging | 1 | 2019 | 39 | 0.140 |
Why?
|
| Biomarkers | 1 | 2019 | 284 | 0.140 |
Why?
|
| Motivation | 1 | 2019 | 103 | 0.140 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 374 | 0.140 |
Why?
|
| Disease Progression | 1 | 2019 | 252 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2018 | 28 | 0.130 |
Why?
|
| Oral Health | 1 | 2018 | 17 | 0.130 |
Why?
|
| Overweight | 1 | 2019 | 262 | 0.130 |
Why?
|
| Weight Reduction Programs | 1 | 2018 | 51 | 0.130 |
Why?
|
| Maternal Behavior | 1 | 2017 | 11 | 0.130 |
Why?
|
| Heart Failure | 1 | 2022 | 403 | 0.120 |
Why?
|
| Social Environment | 1 | 2017 | 77 | 0.120 |
Why?
|
| Weight Gain | 1 | 2018 | 167 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 197 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2019 | 1047 | 0.110 |
Why?
|
| Infant | 3 | 2024 | 1212 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 1233 | 0.100 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 2 | 0.090 |
Why?
|
| Lipocalins | 1 | 2012 | 2 | 0.090 |
Why?
|
| Nephritis, Interstitial | 1 | 2012 | 3 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 31 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2018 | 693 | 0.090 |
Why?
|
| Disclosure | 1 | 2021 | 15 | 0.080 |
Why?
|
| Anxiety | 2 | 2022 | 154 | 0.080 |
Why?
|
| Focus Groups | 1 | 2021 | 140 | 0.080 |
Why?
|
| Age of Onset | 1 | 2020 | 66 | 0.080 |
Why?
|
| Patient Portals | 1 | 2020 | 25 | 0.080 |
Why?
|
| Metformin | 1 | 2020 | 49 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2020 | 93 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 169 | 0.070 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 16 | 0.070 |
Why?
|
| Registries | 1 | 2020 | 449 | 0.070 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2026 | 29 | 0.060 |
Why?
|
| Chicago | 1 | 2016 | 24 | 0.060 |
Why?
|
| Health Resources | 1 | 2016 | 35 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2018 | 235 | 0.060 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2025 | 28 | 0.060 |
Why?
|
| Depression, Postpartum | 1 | 2025 | 27 | 0.060 |
Why?
|
| Developmental Disabilities | 1 | 2025 | 53 | 0.050 |
Why?
|
| Esters | 1 | 2024 | 10 | 0.050 |
Why?
|
| Comorbidity | 1 | 2016 | 516 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2016 | 244 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2023 | 33 | 0.050 |
Why?
|
| Stillbirth | 1 | 2023 | 29 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 19 | 0.050 |
Why?
|
| Diet | 1 | 2024 | 349 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 1204 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 54 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 76 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 96 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 110 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 6 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 2 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 10 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2021 | 16 | 0.040 |
Why?
|
| Glucose | 1 | 2021 | 29 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 161 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2022 | 382 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 568 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 211 | 0.030 |
Why?
|
| North Carolina | 1 | 2018 | 35 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2018 | 88 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 97 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2017 | 108 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2018 | 201 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 291 | 0.030 |
Why?
|
| Medicaid | 1 | 2018 | 189 | 0.030 |
Why?
|
| Weight Loss | 1 | 2018 | 302 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 3 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 6 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 24 | 0.020 |
Why?
|
Concepts
(228)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(23)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->